Prostate Cancer

Nubeqa plus androgen deprivation therapy and docetaxel to treat patients with metastatic hormone-sensitive prostate cancer lowered hospitalization rates but led to marginally longer lengths of stay compared with those treated with placebo, androgen deprivation therapy and docetaxel.

Approximately 40% of patients with metastatic castration-resistant prostate cancer did not undergo certain types of tests that can be instrumental in treatment decisions.

Treatment with Zytiga, prednisone and Erleada plus another treatment regimen improved prostate cancer outcomes and did not change health-related quality of life outcomes.

Lynparza, Zytiga and prednisone led to improved progression-free survival and response rates in patients with metastatic prostate cancer.

Cabometyx plus Tecentriq led to improved progression-free survival compared with novel hormonal therapy in patients with metastatic castration-resistant prostate cancer.

Dexter Scott King, son of Martin Luther King, Jr., died of prostate cancer the same day MLB Hall-of-Famer Ryan Sandberg announced he’s been diagnosed with metastatic disease.

From Michael Strahan announcing his cancer diagnosis to a “Baywatch” star being diagnosed with cancer, here’s what’s happening in the oncology space this week.

Patients continue to be enrolled in a study evaluating the dual-action androgen receptor inhibitor ONCT-534 for the treatment of patients with advanced prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPIs).

The first patients has been dosed within the new CLARIFY trial for patients with prostate cancer awaiting prostatectomy.

Dr. Stephanie Berg of Dana-Farber Cancer Institute and Harvard Medical School discusses the need to be mindful of quality of life when treating prostate cancer.

Dr. Stephanie Berg of the Dana-Farber Cancer Institute and Harvard Medical School discussed the recent EMARK trial which resulted in the FDA’s approval of Xtandi for non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis.

An expert explains the significance of the recent approval of Xtandi for non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR) by the Food and Drug Administration.

Researchers have found that a deeper look at proteins and cells may help explain why prostate cancer tumors often become resistant to hormone therapy.

The first patient has received TLX591, an antibody-based treatment for PSMA-positive metastatic castrate-resistant prostate cancer.

I see a psychologist who is helping me to understand my feelings and to learn mindfulness meditation techniques.

In honor of Men’s Health Awareness Month, CURE® looked back on some of the most significant news within the oncology space.

The Food and Drug Administration approved six new cancer therapies in November 2023.

The Food and Drug Administration approved Xtandi for non-metastatic castration-sensitive prostate cancer at high risk for biochemical recurrence.

My diagnosis of prostate cancer gave me an unsuspected gift.

I was in denial after the shock of being told I had prostate cancer.

Patients with prostate cancer who receive docetaxel with standard-of-care treatment may have a reduced risk of death and an improved prognosis, according to a recent study.

A phase 3 trial found that testosterone recovery after androgen deprivation therapy leads to better quality of life following high-risk prostate cancer.

Recent research has put a spotlight on a number of factors which could be used to estimate which patients with nonmetastatic, unfavorable-risk prostate cancer are at high risk for a shorter time until PSA recurrence and failure.

Prostatic urethra length may help predict which patients with prostate cancer are more likely to experience chronic urinary side effects after radiation treatment, according to a recent study.

According to the Food and Drug Administration, the shortage of Novartis’ prostate cancer treatment Pluvicto, which began in March, has been resolved, with the manufacturer expecting a continued expansion of supply.

Data presented at ESMO “provides strong evidence for an enhanced anti-cancer effect with the combination” of Pluvicto and Xtandi, according to one expert.

Patients with metastatic castration-resistant prostate cancer who were never treated with a taxane derived a progression-free survival benefit from treatment with Pluvicto.

The addition of Keytruda to Xtandi showed no improvements for radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer.

As Susan Sullivan discussed her lung cancer diagnosis and the FDA discusses banning specific hair straightening products due to long-term health effects, here’s what’s happening in the oncology space this week.